Stock & Company Details
Avalyn Pharma Inc. $AVLN
Price:
46,691,331
44M
$1.3B
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
AVLN technical indicators
Latest Avalyn Pharma Inc. (AVLN) technical indicators as of 2026-07-20: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
49.64 2.3%
MACD:
-0.42 13.8%
SMA 50:
$28.73 0.1%
SMA 200:
—
EMA 20:
$28.61 0.0%
Bollinger Bands:
33.05 / 25.64
Stochastic:
30.69 66.6%
ADX 14:
12.05 3.0%
ATR 14:
2.49 3.9%
CCI 20:
-38.88 55.9%
OBV:
4.76M 4.3%
ROC 12:
-5.10% 63.6%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Finance Bot
Ask your questions
Start by typing a question below.
